FTH — Faeth Therapeutics, Share News
0.000.00%
Last trade - 00:00- $459.38m
- $256.60m
Sensei up after receiving and declining Newtyn's buyout proposal
Sensei Biotherapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics Presents Trial-In-Progress Poster For Phase 1/2 Clinical Study Of Sns-101 At Esmo 2023
Sensei Biotherapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics posts Q2 basic EPS USD -0.31
Brief: Sensei Biotherapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of Sns-101, A Conditionally Active Vista-Blocking Antibody, For The Treatment Of Advanced Solid Tumors
Brief: Sensei Biotherapeutics Inc - Entered Into A Purchase Agreement With Apeiron Investment Group Ltd And Others
Brief: Sensei Biotherapeutics Reports Q1 2023 Financial Results And Recent Business Highlights
Sensei Biotherapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Sensei gains as FDA allows testing of cancer therapy in clinical trial
Brief: Sensei Biotherapeutics Announces Ind Clearance By U.S. FDA Enabling Phase 1 Initiation For Sns-101, A Conditionally Active Vista-Blocking Antibody
Brief: Sensei Biotherapeutics Presents New Preclinical Data On Sns-103 Targeting ENTPDase1
Brief: Sensei Biotherapeutics Reports 2022 Of $1.58
Sensei Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Sensei Biotherapeutics Announces Submission Of Investigational New Drug (Ind) Application For Sns-101, A Conditionally Active Vista-Blocking Antibody
Sensei Biotherapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics Holds No Cash Deposits Or Securities At Silicon Valley Bank
Brief: Apeiron Investment Group Says On March 9, Delivered Letter To Sensei Biotherapeutics Nominating Three Candidates To Co's Board - SEC Filing
Sensei Biotherapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview